77 related articles for article (PubMed ID: 10226564)
1. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.
Lin SH; Pu YS; Luo W; Wang Y; Logothetis CJ
Anticancer Res; 1999; 19(1A):337-40. PubMed ID: 10226564
[TBL] [Abstract][Full Text] [Related]
2. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.
Lin SH; Pu YS
Semin Oncol; 1999 Apr; 26(2):227-33. PubMed ID: 10597733
[TBL] [Abstract][Full Text] [Related]
3. The cytoplasmic domain of C-CAM1 tumor suppressor is necessary and sufficient for suppressing the tumorigenicity of prostate cancer cells.
Estrera VT; Luo W; Phan D; Earley K; Hixson DC; Lin SH
Biochem Biophys Res Commun; 1999 Oct; 263(3):797-803. PubMed ID: 10512760
[TBL] [Abstract][Full Text] [Related]
4. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.
Kleinerman DI; Zhang WW; Lin SH; Nguyen TV; von Eschenbach AC; Hsieh JT
Cancer Res; 1995 Jul; 55(13):2831-6. PubMed ID: 7796410
[TBL] [Abstract][Full Text] [Related]
5. C-CAM1 expression: differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells.
Comegys MM; Carreiro MP; Brown JF; Mazzacua A; Flanagan DL; Makarovskiy A; Lin SH; Hixson DC
Oncogene; 1999 May; 18(21):3261-76. PubMed ID: 10359532
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model.
Kleinerman DI; Dinney CP; Zhang WW; Lin SH; Van NT; Hsieh JT
Cancer Res; 1996 Aug; 56(15):3431-5. PubMed ID: 8758907
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains.
Luo W; Wood CG; Earley K; Hung MC; Lin SH
Oncogene; 1997 Apr; 14(14):1697-704. PubMed ID: 9135071
[TBL] [Abstract][Full Text] [Related]
8. C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers.
Wang L; Lin SH; Wu WG; Kemp BL; Walsh GL; Hong WK; Mao L
Clin Cancer Res; 2000 Aug; 6(8):2988-93. PubMed ID: 10955775
[TBL] [Abstract][Full Text] [Related]
9. Tumor-suppressive activity of CD66a in prostate cancer.
Luo W; Tapolsky M; Earley K; Wood CG; Wilson DR; Logothetis CJ; Lin SH
Cancer Gene Ther; 1999; 6(4):313-21. PubMed ID: 10419049
[TBL] [Abstract][Full Text] [Related]
10. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein.
Liang ZH; Wu PH; Li L; Xue G; Zeng YX; Huang WL
Chin Med J (Engl); 2004 Dec; 117(12):1809-14. PubMed ID: 15603709
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.
Hsieh JT; Luo W; Song W; Wang Y; Kleinerman DI; Van NT; Lin SH
Cancer Res; 1995 Jan; 55(1):190-7. PubMed ID: 7805032
[TBL] [Abstract][Full Text] [Related]
13. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470.
Pu YS; Do KA; Luo W; Logothetis CJ; Lin SH
Anticancer Drugs; 2002 Aug; 13(7):743-9. PubMed ID: 12187331
[TBL] [Abstract][Full Text] [Related]
14. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer.
Chen W; Yan C; Hou J; Pu J; Ouyang J; Wen D
Urol Oncol; 2008; 26(4):397-405. PubMed ID: 18367126
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer.
Hsieh JT; Earley K; Pong RC; Wang Y; Van NT; Lin SH
Prostate; 1999 Sep; 41(1):31-8. PubMed ID: 10440873
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
19. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
20. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
